7459
MEDIPAL HOLDINGS CORPORATION
株式会社メディパルホールディングス
Wholesale Trade
Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprising medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; and animal health products for companion animals; and food processing raw materials for agriculture, fisheries, and livestock. In addition, it engages in the contract-based epidemiological studies, clinical studies, etc.; creation of a computerized medical supply database and master product databases for medical facilities; life and non-life insurance agency business; cleaning management; management and operation of distribution centers; commissioned delivery and worker dispatch business; planning, management, administration, and product and service development for the class A health dispensing pharmacies service brand; and distributes specialty pharmaceuticals. Further, the company is involved in contract logistics services; information provision services; health insurance claims review, medical coding dispatch, outsourcing and remote education; and creation of a medical supply database and master product databases for medical facilities. It serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fish producers, and processed food manufacturers. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. Medipal Holdings Corporation was founded in 1898 and is headquartered in Tokyo, Japan.
Price
¥2,747
Market Cap
¥571.2B
Ent. Value
—
Net Cash
est
—
Shares Out.
208.0M
P / E
14.2×
EV / EBIT
—
P / Book
0.92×
P / NCAV
2.65×
Div. Yield
2.26%
Financials
| Metric |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|
| Net Sales | ¥3,671.3B | ¥3,558.7B | ¥3,360.0B | ¥3,290.9B |
| Cost of Sales | ¥3,415.6B | ¥3,312.1B | ¥3,135.7B | ¥3,073.5B |
| Gross Profit | ¥255.8B | ¥246.7B | ¥224.3B | ¥217.4B |
| SG&A | ¥200.1B | ¥199.3B | ¥175.3B | ¥171.8B |
| Operating Income | ¥55.6B | ¥47.3B | ¥49.0B | ¥45.6B |
| Non-Operating Income | ¥16.0B | ¥19.4B | ¥17.6B | ¥17.1B |
| Dividend Income | ¥3.1B | ¥2.8B | ¥2.5B | ¥2.5B |
| Interest Income | ¥50M | ¥29M | ¥101M | ¥177M |
| Non-Operating Expenses | ¥6.4B | ¥2.2B | ¥1.4B | ¥710M |
| Interest Expense | ¥7M | ¥8M | ¥34M | ¥16M |
| Ordinary Income | ¥65.3B | ¥64.6B | ¥65.1B | ¥62.0B |
| Pre-tax Income | ¥76.7B | ¥74.7B | ¥70.1B | ¥57.3B |
| Income Taxes | ¥25.2B | ¥23.0B | ¥21.7B | ¥18.1B |
| Current Tax | ¥24.6B | ¥24.7B | ¥24.0B | ¥20.1B |
| Deferred Tax | ¥637M | ¥-1.7B | ¥-2.3B | ¥-2.0B |
| Net Income (owners) | ¥40.3B | ¥41.5B | ¥38.8B | ¥29.4B |
| Minority Interest | ¥11.2B | ¥10.3B | ¥9.5B | ¥9.8B |
| Comprehensive Income | ¥46.8B | ¥64.7B | ¥51.1B | ¥25.3B |
| EBITDA | ¥74.0B | ¥65.3B | ¥63.6B | ¥60.0B |
| Goodwill Amort. (J-GAAP) | ¥1.3B | ¥1.1B | ¥255M | ¥255M |
| EPS | ¥193.20 | ¥195.83 | ¥184.82 | ¥140.14 |
| Shares Outstanding | 208.0M | 210.0M | 210.0M | 210.0M |
| Shares Issued (total) | 219.2M | 221.3M | 225.5M | 244.5M |
| Treasury Shares | 11.3M | 11.3M | 15.5M | 34.6M |
| Metric |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | ¥1,825.0B | ¥1,799.1B | ¥1,703.9B | ¥1,709.5B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current Assets | ¥1,282.7B | ¥1,244.2B | ¥1,179.3B | ¥1,209.8B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Deposits | ¥261.4B | ¥230.2B | ¥195.0B | ¥243.2B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trade Receivables | ¥749.1B | ¥742.7B | ¥714.8B | ¥699.7B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-Current Assets | ¥542.2B | ¥554.9B | ¥524.6B | ¥499.7B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PP&E | ¥268.6B | ¥271.0B | ¥268.4B | ¥264.4B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Goodwill | ¥13.2B | ¥11.6B | ¥25.0B | ¥604M | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Intangible Assets | ¥39.9B | ¥39.0B | ¥34.2B | ¥10.0B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment Securities | ¥199.1B | ¥210.9B | ¥192.6B | ¥190.8B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred Tax Assets | ¥4.9B | ¥5.4B | ¥5.1B | ¥5.8B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ¥1,067.0B | ¥1,062.5B | ¥1,015.8B | ¥1,060.4B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Current Liabilities | ¥1,009.4B | ¥1,007.7B | ¥971.5B | ¥1,008.8B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounts Payable | ¥932.5B | ¥924.3B | ¥891.0B | ¥908.0B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Taxes Payable | ¥13.3B | ¥13.6B | ¥12.2B | ¥14.1B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-Current Liabilities | ¥57.6B | ¥54.8B | ¥44.3B | ¥51.6B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pension Obligations | ¥16.1B | ¥16.6B | ¥16.9B | ¥16.4B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deferred Tax Liab. | ¥32.9B | ¥34.1B | ¥23.4B | ¥25.6B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | ¥757.9B | ¥736.6B | ¥688.1B | ¥649.1B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Stock | ¥22.4B | ¥22.4B | ¥22.4B | ¥22.4B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Surplus | ¥100.0B | ¥99.8B | ¥101.6B | ¥133.9B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Retained Earnings | ¥463.1B | ¥439.3B | ¥414.7B | ¥385.6B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Treasury Stock | ¥-22.2B | ¥-21.3B | ¥-26.3B | ¥-58.6B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AOCI | ¥56.3B | ¥60.1B | ¥48.9B | ¥47.0B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity (owners) | ¥563.3B | ¥540.3B | ¥512.4B | ¥483.3B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Minority Interests | ¥138.4B | ¥136.3B | ¥126.7B | ¥118.8B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Cash ⓘ | ¥261.4B | ¥230.2B | ¥195.0B | ¥243.2B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| NCAV ⓘ | ¥215.7B | ¥181.7B | ¥163.5B | ¥149.4B | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| NCAV/Share | ¥1,037 | ¥865 | ¥779 | ¥711 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BV/Share | ¥2,709 | ¥2,572 | ¥2,441 | ¥2,302 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Metric |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|
| Operating CF | ¥60.6B | ¥61.8B | ¥16.1B | ¥61.2B |
| Interest Paid | ¥-10M | ¥-5M | ¥-34M | ¥-16M |
| Interest Received | ¥4.9B | ¥6.0B | ¥4.8B | ¥4.7B |
| D&A | ¥17.1B | ¥16.9B | ¥14.4B | ¥14.1B |
| Goodwill Amort. | ¥1.3B | ¥1.1B | ¥255M | ¥255M |
| Investing CF | ¥-3.4B | ¥-7.8B | ¥-39.5B | ¥-24.3B |
| CapEx | ¥8.9B | ¥15.6B | ¥10.5B | ¥16.0B |
| Purchase Investments | ¥-555M | ¥-1.1B | ¥-799M | ¥-6.8B |
| Financing CF | ¥-25.9B | ¥-25.2B | ¥-43.5B | ¥-16.5B |
| Dividends Paid | ¥-12.5B | ¥-11.2B | ¥-9.7B | ¥-8.8B |
| Share Buybacks | ¥-5.1B | ¥-10.1B | ¥-1M | ¥-1M |
| LT Debt Repaid | — | — | — | ¥-350M |
| Free Cash Flow | ¥51.7B | ¥46.3B | ¥5.7B | ¥45.3B |
| Net Change in Cash | ¥31.3B | ¥28.8B | ¥-66.9B | ¥20.4B |
| Metric |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|
| ROE | 6.6% | 7.1% | 7.1% | 5.6% |
| ROA | 2.2% | 2.4% | 2.3% | 1.7% |
| EPS | ¥193.20 | ¥195.83 | ¥184.82 | ¥140.14 |
| DPS | ¥62.00 | ¥60.00 | ¥46.00 | ¥44.00 |
| BPS | ¥2,979.39 | ¥2,858.57 | ¥2,673.62 | ¥2,525.72 |
| FCF/Share | ¥249 | ¥220 | ¥27 | ¥216 |
| NCAV/Share | ¥1,037 | ¥865 | ¥779 | ¥711 |
| Payout Ratio | 32.1% | 30.6% | 24.9% | 31.4% |
Event Timeline
S Shareholder
A Capital Signal
Large Shareholder Reports 1
Capital Allocation Signals 2
| Date | Type | Amount | Summary | |
|---|---|---|---|---|
|
2026-05-14
15:30
|
Div Increase | ¥7.0B ¥34.0/sh +6% | MEDIPAL Holdings announced a dividend increase for FY2026 (ended March 31, 2026), raising the year-end dividend from 32 … | |
|
Summary
MEDIPAL Holdings announced a dividend increase for FY2026 (ended March 31, 2026), raising the year-end dividend from 32 yen to 34 yen per share (+2 yen or +6.25% vs prior forecast). Combined with the interim dividend of 32 yen already paid, the full-year dividend reaches 66 yen per share, up from 62 yen in the prior year. Total dividend payout is 6,959 million yen.
YoY: +6%
Source (JP)
2026年3月期の期末配当金につきましては、上記の方針及び当期の財務状況等を踏まえ、従来予想から2円増額し、1株当たり34円00銭にすることを決議いたしました。
剰余金の配当(増配)に関するお知らせ
TDnet PDF
|
||||
|
2026-05-11
16:30
|
TOB | ¥6650.0/sh 14.3% | Medipal Holdings announced a tender offer to acquire all outstanding shares of PALTAC (TSE Prime, code 8283) at ¥6,650 p… | |
|
Summary
Medipal Holdings announced a tender offer to acquire all outstanding shares of PALTAC (TSE Prime, code 8283) at ¥6,650 per share for complete subsidiary acquisition. The offer runs from May 12 to July 7, 2026, with a minimum acceptance threshold of 8,676,100 shares (14.27%) to achieve 66.67% voting control; PALTAC's board supports the offer and recommends shareholder participation.
Deadline: 2026-07-07
% of Shares: 14.3%
Shares: 8,676,100
Source (JP)
株式会社メディパルホールディングスは、株式会社PALTACの普通株式を金融商品取引法に基づく公開買付けにより取得することを決議いたしました。買付け等の価格は普通株式1株につき、金6,650円。買付予定数の下限は8,676,100株。対象者は本公開買付けに賛同し、対象者の株主の皆様が本公開買付けに応募することを推奨する。
株式会社PALTAC株式(証券コード:8283)に対する公開買付けの開始に関するお知らせ
TDnet PDF
|
||||
| # | Shareholder | Shares (thou.) | % of Total |
|---|---|---|---|
| 1 |
Japan Master Trust Bank
日本マスタートラスト信託銀行株式会社(信託口)
|
30,652 | 14.74% |
| 2 |
NORTHERN TRUST CO. (AVFC) RE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE EQUITY TRUST
NORTHERN TRUST CO. (AVFC) RE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE EQUITY TRUST (常任代理人 香港上海銀行東京支店 カストディ業務部)
|
11,120 | 5.35% |
| 3 |
Japan Custody Bank
株式会社日本カストディ銀行(信託口)
|
9,229 | 4.44% |
| 4 |
STATE STREET BANK AND TRUST COMPANY
STATE STREET BANK AND TRUST COMPANY 505001 (常任代理人 株式会社みずほ銀行決済営業部)
|
7,424 | 3.57% |
| 5 |
NORTHERN TRUST CO.(AVFC) RE U.S. TAX EXEMPTED PENSION FUNDS
NORTHERN TRUST CO.(AVFC) RE U.S. TAX EXEMPTED PENSION FUNDS (常任代理人 香港上海銀行東京支店 カストディ業務部)
|
6,089 | 2.93% |
| 6 |
Employee Stock Ownership Plan
MPグループメディセオ従業員持株会
|
5,119 | 2.46% |
| 7 |
KOBAYASHI PHARMACEUTICAL CO.,LTD.
小林製薬株式会社
|
5,074 | 2.44% |
| 8 |
NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT
NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT (常任代理人 香港上海銀行東京支店 カストディ業務部)
|
4,648 | 2.24% |
| 9 |
STATE STREET BANK AND TRUST COMPANY
STATE STREET BANK AND TRUST COMPANY 505103 (常任代理人 株式会社みずほ銀行決済営業部)
|
3,980 | 1.91% |
| 10 |
NORTHERN TRUST CO.(AVFC) RE IEDU UCITS CLIENTS NON LENDING 15 PCT TREATY ACCOUNT
NORTHERN TRUST CO.(AVFC) RE IEDU UCITS CLIENTS NON LENDING 15 PCT TREATY ACCOUNT (常任代理人 香港上海銀行東京支店 カストディ業務部)
|
3,330 | 1.60% |
as of 2025-03-31
Source: EDINET ↗
Ownership by year — hover bars for detail
Domestic Nominees
19.2%
+1.3% vs 2024
Trust bank custodians — GPIF, pensions, investment trusts
Foreign Custodians
0.0%
+0.0% vs 2024
Sub-custodians for foreign asset managers
Direct / Strategic
22.5%
+1.3% vs 2024
Named entities with disclosed investment intent
Bar = % of shares outstanding · top-10 covers 41.7% · grey = other shareholders · 2025
| Shareholder | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Japan Master Trust Bank 日本マスタートラスト信託銀行 | 13.78% | 13.60% | 14.74% +1.14% | |
| NORTHERN TRUST CO. (AVFC) RE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE EQUITY TRUST NORTHERN TRUST CO. (AVFC) RE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE EQUITY TRUST | 6.07% | 5.44% | 5.35% -0.09% | |
| Japan Custody Bank 日本カストディ銀行 | 6.74% | 4.31% | 4.44% +0.13% | |
| STATE STREET BANK AND TRUST COMPANY STATE STREET BANK AND TRUST COMPANY 505001 | 2.85% | 2.77% | 3.57% +0.80% | |
| NORTHERN TRUST CO.(AVFC) RE U.S. TAX EXEMPTED PENSION FUNDS NORTHERN TRUST CO.(AVFC) RE U.S. TAX EXEMPTED PENSION FUNDS | 3.04% | 2.75% | 2.93% +0.18% | |
| Employee Stock Ownership Plan MPグループメディセオ従業員持株会 | 2.83% | 2.56% | 2.46% -0.10% | |
| KOBAYASHI PHARMACEUTICAL CO.,LTD. 小林製薬 | 2.42% | 2.42% | 2.44% +0.02% | |
| NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT | 2.05% | 2.05% | 2.24% +0.19% | |
| STATE STREET BANK AND TRUST COMPANY STATE STREET BANK AND TRUST COMPANY 505103 | — | 1.66% | 1.91% +0.25% | |
| NORTHERN TRUST CO.(AVFC) RE IEDU UCITS CLIENTS NON LENDING 15 PCT TREATY ACCOUNT NORTHERN TRUST CO.(AVFC) RE IEDU UCITS CLIENTS NON LENDING 15 PCT TREATY ACCOUNT | 1.82% | 1.56% | 1.60% +0.04% | |
| Concentration (HHI) ⓘ | 311 | 270 | 310 |
3 fiscal years · top-10 holders per year · >2,500 HHI = high concentration · entity-resolved
Portfolio Book Value
¥92,225M
+0% since 2023
Holdings
53
+5 new
4 exited
Trend
2 unwinding
vs 2023
| Held Company | FY2025 ¥92,225M total | FY2023 ¥91,773M total | |||
|---|---|---|---|---|---|
| Book Val ¥M | Shares | Book Val ¥M | Shares | ||
|
Otsuka Holdings Co., Ltd.
大塚ホールディングス㈱
|
41,214 |
-13.5%
↓
5,316,000
|
25,840 | 6,148,000 | M |
|
DAIICHI SANKYO COMPANY, LIMITED
第一三共㈱
|
9,023 |
-49.4%
↓
2,570,089
|
24,496 | 5,080,089 | M |
|
TERUMO CORPORATION
テルモ㈱
|
6,133 |
+79.6%
↑
2,192,968
|
4,364 | 1,221,084 | M |
| ㈱EMシステムズ | 5,601 |
7,063,200
|
5,954 | 7,063,200 | |
|
TSUMURA & CO.
㈱ツムラ
|
3,659 |
+0.5%
↑
848,159
|
2,220 | 844,183 | M |
|
Eisai Co., Ltd.
エーザイ㈱
|
2,909 |
701,975
|
5,267 | 701,975 | M |
|
HOGY MEDICAL CO.,LTD.
㈱ホギメディカル
|
2,803 |
584,000
|
1,854 | 584,000 | M |
|
ONO PHARMACEUTICAL CO., LTD.
小野薬品工業㈱
|
2,688 |
1,677,615
|
4,636 | 1,677,615 | M |
|
MTI Co., Ltd.
㈱エムティーアイ
|
2,668 |
3,150,000
|
1,814 | 3,150,000 | |
|
Shionogi & Co.,Ltd.
塩野義製薬㈱
|
2,279 |
+200.0%
↑
1,014,795
|
2,021 | 338,265 | M |
|
Takeda Pharmaceutical Company Limited
武田薬品工業㈱
|
2,260 |
512,263
|
2,228 | 512,263 | |
|
繝。繝�繧」繧ォ繝ォ繝サ繝�繝シ繧ソ繝サ繝薙ず繝ァ繝ウ譬ェ蠑丈シ夂、セ
メディカル・データ・ビジョン㈱
|
1,294 |
3,212,600
|
2,907 | 3,212,600 | |
|
Nippon Shinyaku Co.,Ltd.
日本新薬㈱
|
1,024 |
269,372
|
1,570 | 269,372 | M |
|
�シィ�ス��ス��ス抵ス費ス難ス��ス��ス�譬ェ蠑丈シ夂、セ
Heartseed㈱
|
911 |
NEW
New
416,000
|
— | ||
|
TORII PHARMACEUTICAL CO., LTD.
鳥居薬品㈱
|
775 |
168,988
|
537 | 168,988 | M |
|
Meiji Holdings Co., Ltd.
明治ホールディングス㈱
|
771 |
+100.0%
↑
237,308
|
748 | 118,654 | M |
|
HISAMITSU PHARMACEUTICAL CO.,INC.
久光製薬㈱
|
757 |
+4.8%
↑
187,123
|
674 | 178,531 | M |
|
Sumitomo Pharma Co., Ltd.
住友ファーマ㈱
|
671 |
921,788
|
746 | 921,788 | M |
|
SANTEN PHARMACEUTICAL CO.,LTD.
参天製薬㈱
|
661 |
466,545
|
527 | 466,545 | M |
|
KAKEN PHARMACEUTIAL CO., LTD.
科研製薬㈱
|
580 |
129,565
|
478 | 129,565 | M |
|
莉、蜥後い繧ォ繧ヲ繝ウ繝�繧」繝ウ繧ー繝サ繝帙�シ繝ォ繝�繧」繝ウ繧ー繧ケ譬ェ蠑丈シ夂、セ
令和アカウンティング・ホールディングス㈱
|
375 |
NEW
New
625,000
|
— | ||
| Chordia Therapeutics(株) | 350 |
NEW
New
1,307,100
|
— | ||
|
KISSEI PHARMACEUTICAL CO.,LTD.
キッセイ薬品工業㈱
|
338 |
+1.7%
↑
88,089
|
228 | 86,606 | M |
|
SHINYEI KAISHA
神栄㈱
|
336 |
208,500
|
178 | 208,500 | |
|
ARIAKE JAPAN Co.,Ltd.
アリアケジャパン㈱
|
309 |
50,000
|
244 | 50,000 | |
|
KYORIN Pharmaceutical Co., Ltd.
杏林製薬㈱
|
300 |
NEW
New
200,000
|
— | M | |
|
SAWAI GROUP HOLDINGS Co., Ltd.
サワイグループホールディングス㈱
|
290 |
+200.0%
↑
146,400
|
178 | 48,800 | M |
| ㈱PRISM BioLab | 258 |
NEW
New
922,400
|
— | ||
|
Mochida Pharmaceutical Co.,Ltd.
持田製薬㈱
|
238 |
74,882
|
250 | 74,882 | M |
|
ZERIA PHARMCEUTICAL CO., LTD.
ゼリア新薬工業㈱
|
230 |
102,300
|
229 | 102,300 | M |
|
ROHTO PHARMACEUTICAL CO.,LTD.
ロート製薬㈱
|
110 |
49,508
|
137 | 49,508 | M |
|
Nipro Co., Ltd.
ニプロ㈱
|
108 |
79,784
|
81 | 79,784 | M |
|
OHMOTO GUMI CO.,LTD
㈱大本組
|
74 |
+500.0%
↑
60,000
|
73 | 10,000 | M |
|
譬ェ蠑丈シ夂、セ繝輔ぃ繝ウ繝壹ャ繝�
㈱ファンペップ
|
68 |
595,200
|
130 | 595,200 | |
|
NIPPON KAYAKU CO.,LTD.
日本化薬㈱
|
54 |
38,551
|
46 | 38,551 | M |
|
Fuso Pharmaceutical Industries,Ltd.
扶桑薬品工業㈱
|
34 |
14,301
|
28 | 14,301 | M |
|
FUMAKILLALIMITED
フマキラー㈱
|
22 |
20,786
|
22 | 20,786 | M |
|
KOBAYASHI PHARMACEUTICAL CO.,LTD.
小林製薬㈱
|
17 |
3,000
|
24 | 3,000 | M |
|
Vital KSK Holdings Co., Ltd.
㈱バイタルケーエスケー・ホールディングス
|
14 |
11,361
|
10 | 11,361 | M |
|
Medical Ikkou Group Co.,Ltd.
㈱メディカル一光グループ
|
7 |
3,200
|
7 | 3,200 | |
|
SUZUKEN CO.,LTD.
㈱スズケン
|
4 |
1,000
|
3 | 1,000 | |
|
TOHO HOLDINGS CO.,LTD.
東邦ホールディングス㈱
|
4 |
1,000
|
2 | 1,000 | M |
| アルフレッサ ホールディングス㈱ | 2 |
1,000
|
1 | 1,000 | M |
|
Kanda Holdings Co.,Ltd
カンダホールディングス㈱
|
1 |
+100.0%
↑
2,200
|
1 | 1,100 | M |
|
Hokuyaku Takeyama Holdings Co., Ltd.
㈱ほくやく・竹山ホールディングス
|
1 |
1,886
|
1 | 1,886 | M |
|
AIN HOLDINGS INC.
㈱アインホールディングス
|
— | — | |||
|
Nichi-Iko Pharmaceutical Co.
日医工㈱
|
— | — | M | ||
|
Astellas Pharma Inc.
アステラス製薬㈱
|
— | — | |||
|
Kyowa Kirin Co.,Ltd.
協和キリン㈱
|
— | — | |||
|
Mitsubishi UFJ Financial Group, Inc.
㈱三菱UFJフィナンシャル・グループ
|
— | — | M | ||
|
Mizuho Financial Group, Inc.
㈱みずほフィナンシャルグループ
|
— | — | M | ||
|
Sumitomo Mitsui Financial Group, Inc.
㈱三井住友フィナンシャルグループ
|
— | — | |||
|
Resona Holdings, Inc.
㈱りそなホールディングス
|
— | — | |||
|
ASKA Pharmaceutical Holdings CO., Ltd.
あすか製薬ホールディングス㈱
|
— |
−100%
Exit
—
|
398 | 335,000 | M |
|
Mitsubishi Chemical Gloup Corporation
三菱ケミカルグループ㈱
|
— |
−100%
Exit
—
|
255 | 325,600 | M |
| キョーリン製薬ホールディングス㈱ | — |
−100%
Exit
—
|
340 | 200,000 | M |
|
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
大正製薬ホールディングス㈱
|
— |
−100%
Exit
—
|
26 | 4,809 | M |
| Portfolio total | 92,225 | 91,773 | |||
Book value in ¥M · ↓ reduced · ↑ increased vs prior year · M = mutual holding